D
Intellia Therapeutics, Inc.
NTLA
$23.88
$0.160.68%
D
Sell
3/14/2023Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 7.09 to 6.35.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 7.09 to 6.35.
D
Sell
5/31/2022Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index.
D
Sell
5/13/2022Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$1.0915 to -$1.9648, EBIT declined 79.38% from -$80.42M to -$144.25M, and operating cash flow declined 46.02% from -$54.65M to -$79.8M.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$1.0915 to -$1.9648, EBIT declined 79.38% from -$80.42M to -$144.25M, and operating cash flow declined 46.02% from -$54.65M to -$79.8M.
D
Sell
5/5/2022Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.21 to 5.97.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.21 to 5.97.
D
Sell
11/23/2021Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and valuation index.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and valuation index.
D
Sell
11/8/2021Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and valuation index. Operating cash flow declined 22.73% from -$52.98M to -$65.02M, and EBIT declined 4.31% from -$69.02M to -$71.99M.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and valuation index. Operating cash flow declined 22.73% from -$52.98M to -$65.02M, and EBIT declined 4.31% from -$69.02M to -$71.99M.
D
Sell
10/16/2020Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 10/16/2020 due to a decline in the solvency index and valuation index.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 10/16/2020 due to a decline in the solvency index and valuation index.
D
Sell
8/7/2020Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 248.96% from -$38.55M to $57.42M, total revenue increased 25.91% from $12.92M to $16.26M, and earnings per share increased from -$0.6299 to -$0.607.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 248.96% from -$38.55M to $57.42M, total revenue increased 25.91% from $12.92M to $16.26M, and earnings per share increased from -$0.6299 to -$0.607.
D
Sell
10/3/2018Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 10/3/2018 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 26.59% from -$17.77M to -$22.5M, EBIT declined 5.19% from -$22.43M to -$23.6M, and the quick ratio declined from 13.1 to 12.48.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 10/3/2018 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 26.59% from -$17.77M to -$22.5M, EBIT declined 5.19% from -$22.43M to -$23.6M, and the quick ratio declined from 13.1 to 12.48.
D
Sell
7/30/2018Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 7/30/2018 due to an increase in the total return index, volatility index and solvency index.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 7/30/2018 due to an increase in the total return index, volatility index and solvency index.
D
Sell
5/2/2018Downgrade
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 5/2/2018 due to a decline in the total return index, growth index and efficiency index. Total capital declined 1.7% from $300.6M to $295.5M.
Intellia Therapeutics, Inc. (NTLA) was downgraded to D from D+ on 5/2/2018 due to a decline in the total return index, growth index and efficiency index. Total capital declined 1.7% from $300.6M to $295.5M.
D
Sell
3/16/2018Upgraded
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 3/16/2018 due to an increase in the solvency index, total return index and efficiency index. Total capital increased 70.94% from $175.85M to $300.6M, and the quick ratio increased from 8.79 to 11.2.
Intellia Therapeutics, Inc. (NTLA) was upgraded to D+ from D on 3/16/2018 due to an increase in the solvency index, total return index and efficiency index. Total capital increased 70.94% from $175.85M to $300.6M, and the quick ratio increased from 8.79 to 11.2.
D
Sell
11/29/2017Downgrade
Intellia Therapeutics Inc. (NTLA) was downgraded to D from D+ on 11/29/2017 due to a decline in the total return index.
Intellia Therapeutics Inc. (NTLA) was downgraded to D from D+ on 11/29/2017 due to a decline in the total return index.
D
Sell
11/14/2017Upgraded
Intellia Therapeutics Inc. (NTLA) was upgraded to D+ from D on 11/14/2017 due to a substantial increase in the total return index, growth index and efficiency index. Total revenue increased 23.66% from $5.92M to $7.32M, earnings per share increased from -$0.4466 to -$0.4364, and net income increased 1.52% from -$15.59M to -$15.36M.
Intellia Therapeutics Inc. (NTLA) was upgraded to D+ from D on 11/14/2017 due to a substantial increase in the total return index, growth index and efficiency index. Total revenue increased 23.66% from $5.92M to $7.32M, earnings per share increased from -$0.4466 to -$0.4364, and net income increased 1.52% from -$15.59M to -$15.36M.
D
Sell
8/18/2017Upgraded
Intellia Therapeutics Inc. (NTLA) was upgraded to D from D- on 8/18/2017 due to an increase in the volatility index and total return index.
Intellia Therapeutics Inc. (NTLA) was upgraded to D from D- on 8/18/2017 due to an increase in the volatility index and total return index.
D
Sell
8/3/2017Downgrade
Intellia Therapeutics Inc. (NTLA) was downgraded to D- from D on 8/3/2017 due to a noticeable decline in the efficiency index, growth index and solvency index. Operating cash flow declined 37.55% from -$11.4M to -$15.68M, EBIT declined 23.7% from -$12.95M to -$16.02M, and net income declined 23.45% from -$12.63M to -$15.59M.
Intellia Therapeutics Inc. (NTLA) was downgraded to D- from D on 8/3/2017 due to a noticeable decline in the efficiency index, growth index and solvency index. Operating cash flow declined 37.55% from -$11.4M to -$15.68M, EBIT declined 23.7% from -$12.95M to -$16.02M, and net income declined 23.45% from -$12.63M to -$15.59M.
D
Sell
6/1/2017Upgraded
Intellia Therapeutics Inc. (NTLA) was upgraded to D from D- on 6/1/2017 due to an increase in the total return index.
Intellia Therapeutics Inc. (NTLA) was upgraded to D from D- on 6/1/2017 due to an increase in the total return index.
D
Sell
2/1/2017Upgraded
Intellia Therapeutics Inc. (NTLA) was upgraded to D- from E on 2/1/2017 due to a noticeable increase in the efficiency index and growth index. Earnings per share increased from -$0.3609 to -$0.218, and total revenue increased 15.76% from $4.21M to $4.87M.
Intellia Therapeutics Inc. (NTLA) was upgraded to D- from E on 2/1/2017 due to a noticeable increase in the efficiency index and growth index. Earnings per share increased from -$0.3609 to -$0.218, and total revenue increased 15.76% from $4.21M to $4.87M.
E
Sell
11/1/2016Upgraded
Intellia Therapeutics Inc. (NTLA) was upgraded to E from E- on 11/1/2016 due to a significant increase in the solvency index and growth index. Operating cash flow increased 817.02% from -$9.42M to $67.55M, total revenue increased 136.69% from $1.78M to $4.21M, and the quick ratio increased from 5.95 to 13.96.
Intellia Therapeutics Inc. (NTLA) was upgraded to E from E- on 11/1/2016 due to a significant increase in the solvency index and growth index. Operating cash flow increased 817.02% from -$9.42M to $67.55M, total revenue increased 136.69% from $1.78M to $4.21M, and the quick ratio increased from 5.95 to 13.96.
E
Sell
8/1/2016None
Intellia Therapeutics, Inc. (NTLA) was downgraded to E- from U on 08/01/2016.
Intellia Therapeutics, Inc. (NTLA) was downgraded to E- from U on 08/01/2016.
NASDAQ
05/07/2024 4:00PM Eastern
Quotes delayed
